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Abstract 
 
Cancer is a disorder with various genetic and epigenetic alterations. Genetic alterations such as 
mutations, i.e., substitutions, amplifications, and deletions of nucleotide sequences, are largely 
irreversible, whereas epigenetic alterations can be modified by pharmacological agents that 
target components of the epigenetic machinery. Recent studies have showed that introduction of 
defined factors such as those encoded by c-MYC, SOX2, OCT3/4, and KLF4 in normal somatic 
cells results in their dedifferentiation into induced pluripotent stem (iPS) cells. In addition, we 
have reported that these iPS factors induce the development of induced multipotent cancer (iPC) 
cells from gastrointestinal cancer cells by reducing tumor aggressiveness. The efficiency of iPS 
reprogramming increased when p53 was inhibited. The study of cancer cells suggests that the 
p53 pathways might be involved in the aggressive phenotypes of iPC cells in a long-term culture. 
However, the roles of gain-of-function oncogenic mutations in TP53, which is a key tumor 
suppressor gene, remain to be elucidated. We investigated reprogramming efficiency of iPS 
generation in human diploid fibroblasts that were co-transfected with TP53 mutants and defined 
factors. The results suggest that mutations in those TP53 regions that are involved in DNA 
contact might play a critical role in the efficiency of iPS generation. Taken together, our studies 
suggest 2 roles of TP53 mutations in reprogramming: (1) the structural mutations might 
contribute to, or collaborate with, other mutations to regulate the maintenance of genomic 
stability; (2) the DNA-contact mutations could affect the downstream target genes, which may be 
distinct from those involved in wild-type p53 function. These molecular manipulations of 
tumorigenicity and enhancement of cellular reprogramming efficiency by the p53 pathway will 
open an attractive and useful avenue for future medicine. 
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Introduction 
 
Although whether complete cellular reprogramming occurred through epigenomic modifications, 
rather than by the cell fusion approach, remained debatable, the discovery that complete 
reprogramming could be achieved by introducing defined transcription factors Oct4 (also known 
as Pou5f1), Sox2, Klf4, and c-Myc into the terminally differentiated somatic fibroblasts of mouse 
(1) and human origins (2) was an important breakthrough. The generation of induced pluripotent 
stem (iPS) cells by introducing defined factors, which are generally expressed in embryonic stem 
(ES) cells, results in the reconstitution of organs in chimeric mice and can contribute in the 
regeneration of human tissues (3). The generation of iPS cells is believed to require epigenetic 
modifications, although the precise mechanism remains to be fully elucidated (3). We recently 
showed that gastrointestinal cancer cells acquired multipotential differentiation ability on 
introducing defined factors, i.e., the gene expression profiles of mesoderm and ectoderm 
appeared in those gastrointestinal cancer cells of endodermal origin (induced multipotent cancer 
(iPC) cells) (4). In a recent reprogramming study using cancer cells with gain-of-function 
mutations such as TP53
R175H
 and KRAS
G12D
, we demonstrated multipotency of differentiation 
and temporal suppression of tumorigenicity; however, the cells subsequently resumed growth in 
long-term culture (>2 months) and exhibited increased tumorigenicity. Following iPS 
factor-mediated reprogramming of HuCC-T1 cholangiocellular carcinoma cells harboring 
gain-of-function mutations, the expression of all ES-like genes, except activated endogenous 
c-MYC, was downregulated in the iPC cells, suggesting a role of such oncogenic mutations in 
the reactivation of malignant phenotype in long-term culture in vitro (5), presumably via the 
accumulation of further mutations or increased genomic instability. Recent studies have shown 
that decreasing the level of p53, a tumor suppressor protein, can induce murine fibroblasts to 
dedifferentiate into iPS cells that are capable of generating germline-transmitting chimeric mice, 
suggesting that p53 is not necessary for reprogramming. In fact, silencing or deleting TP53 
significantly increases the reprogramming efficiency of human somatic cells (6-8). Furthermore, 
results from tumorigenicity assays using HCT116 TP53-null cells indicate that in vitro cultured 
post-iPC cells exhibit increased tumor formation in vivo (unpublished data). The present results 
suggest that reprogramming-based, novel therapeutic approaches involving the siRNA inhibition 
of p53 pathway (6-8) and hypoxia (9) will be beneficial for inhibiting in vivo tumorigenesis in 
normal iPS cells. 
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Materials and Methods 
 
Transduction of human cancer cell lines 
The transfection of defined factors was performed as described previously (4). Transfections with 
lentivirus were performed using the Virapower Lentiviral Packaging Mix (Invitrogen, Carlsbad, 
CA). Retroviral transfections were performed using the ViraDuctin retrovirus transduction kit (Cell 
Biolabs, San Diego, CA). Briefly, Slc7a1 (receptor gene) was introduced into human fibroblasts 
with lentivirus to improve transduction efficiency. Then, 4 combinations of retroviruses encoding 
Oct4, Sox2, Klf4, and c-Myc were introduced into human fibroblasts expressing Slc7a1. 
Co-transfections were performed using retroviral wild type and mutant TP53 vectors (described 
below). After a week, the medium (DMEM with 10% FBS) was replaced with a medium suitable 
for ES cell culture, i.e., mTeSR1 medium (StemCell Technologies, Vancouver, BC, Canada) or 
MEF-conditioned maintenance medium. To assess transfection efficiency, DsRed (Clontech, 
Palo Alto, CA) was introduced into the cell lines with an ecotropic retrovirus produced in PLAT-E 
packaging cells. GFP expression in the transfectants was visualized using a fluorescence 
microscope (BZ-8000; Keyence, Osaka, Japan). All-in-one-type fluorescence microscopy 
(BZ-8000) with digital photographic capability was used to visualize cells at different 
magnifications.  
 
Mutant Vectors 
The wild-type and mutant TP53 (V143A, R175H, R248W, R249S, and R273H) containing pCMV 
plasmids were purchased from Addgene, and the insert cDNAs were amplified by PCR using the 
forward and reverse primers TTTGGATCCCTGCCATGGAGGAGCC and 
TTTCTCGAGAATGTCTGTCTGAGTCAGG, respectively. The PCR products were separated by 
agarose gel electrophoresis and recovered from the gel with Qiagen extraction kit. The PCR 
products were digested with the restriction enzymes BamHI and XhoI, and the samples were 
purified using Qiagen PCR purification kit. The retroviral vector pMXs (Cell Biolabs) were 
digested using BamHI and XhoI, and purified using Qiagen PCR purification kit. The wild-type 
and mutant TP53 cDNAs were ligated into retroviral vector pMXs, and transformed into 
Escherichia coli (DH10B). The sizes and sequences of insert cDNAs were verified by digestion 
with BamHI and XhoI and DNA sequencing.  
 
RT-PCR 
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5 
For the assessment of PCR amplification products of various sizes, quantitative real-time 
RT-PCR was performed using primers for specific genes and GAPDH using a LightCycler 
TaqMan Master Kit (Roche Diagnostics, Tokyo, Japan), as described previously (4).  
 
Reagents and antibodies 
For immunocytology, antibodies against Nanog, Ssea-4, Tra-1-60, Tra-1-81, and Tra-2-49 
(Chemicon International, Inc., Temecula, CA) were used. 
 
Statistical analysis 
For continuous variables, the results are expressed as mean ± standard error values. 
Relationships among gene expression levels or cell counts were analyzed by the chi-square and 
Wilcoxon rank tests. All data were analyzed using the JMP software (SAS Institute, Cary, NC). 
Differences with p < 0.05 were considered statistically significant. 
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Results and Discussion 
 
Co-expression of TP53 mutants in cellular reprogramming 
Reportedly, the introduction of 4 defined factors including OCT4, SOX2, KLF4, and c-MYC can 
reprogram the terminally differentiated human fibroblast cells into iPS cells. Retroviral-mediated 
gene transfer of OCT4, SOX2, KLF4, and c-MYC was performed after transfection of the Slc7a1 
receptor gene. After a week, the medium (DMEM with 10% FBS) was replaced with a medium 
suitable for ES cell culture, mTeSR1 medium (Fig. 1A). Microscopic analysis indicated that the 
flattened, spindle-shaped fibroblasts had changed their morphology to round spheres (Fig. 1B-D), 
which is a characteristic of iPS cells (1, 2). To assess the transfection efficiency, we introduced 
DsRed (Clontech) into the cell lines via an ecotropic retrovirus produced in PLAT-E packaging 
cells. Visualization by fluorescence microscopy indicated that >80% cells expressed Gfp (data 
not shown). Since ES-like protein expression is a marker for cellular reprogramming, we 
assessed the expression of Ssea-4, Tra-1-60, Tra-1-81, and Tra-2-49 proteins by 
immunostaining. As seen in Figure 2, Ssea-4, Tra-1-60, Tra-1-81, and Tra-2-49 proteins were 
expressed in the generated iPS cells, confirming the reprogramming process (1, 2). Next, we 
counted the number of ES-like spheres (Fig. 3). We found that 240 or 120 ES-like spheres were 
respectively form by co-transfection of TP53 (R248W) or TP53 (R249S) with the 4 defined 
factors, whereas 20–40 colonies were formed by transfection of 3 or 4 defined factors. These 
findings are compatible with those from previous reports (1, 2).  
 
A gain-of-function of mutated or deficient p53 in cellular reprogramming 
Recent studies have shown that decreasing p53 level can induce murine fibroblasts to 
dedifferentiate into iPS cells that have the capability of generating germline-transmitting chimeric 
mice, suggesting that p53 may not be necessary for reprogramming, In fact, silencing or deleting 
p53 significantly increases the efficiency of somatic cell reprogramming to a pluripotent state 
(6-8). TP53 is mutated in a large fraction of human tumors, and many mutated forms of p53 gain 
novel functions. Recently, the effect of mutant p53 (R172H) on somatic cell reprogramming has 
been reported (10). This report compared the reprogramming efficiency of murine fibroblasts 
(MEFs) derived from p53-knockout mice with those of MEFs derived from homozygous mutant 
p53 (R172H)-knockin mice harboring an arginine-to-histidine substitution at position 172 (11), 
which corresponded to the R175H hotspot mutation in humans. The data indicated a 
gain-of-function property of the mutant p53 (R172H), which markedly enhanced the 
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reprogramming efficiency compared to p53 deficiency (10). Although the p53-knockout cells 
reprogrammed with only OCT4 and SOX2 maintained their pluripotent capacity in vivo, 
reprogrammed cells expressing mutant p53 (R172H) lost this capability and gave rise to 
malignant tumors (10). The overexpression of KLF4 in either p53-knockout or mutant p53 
(R172H)-knockin cells induced aggressive tumors, indicating an oncogenic activity of KLF4 in 
the p53-deficient or mutated background (10). This novel activity of mutant p53 (R172H) was 
manifested as alterations in the characteristics of the reprogrammed cells (10), although critical 
roles of other mutations remain to be investigated.  
 
Various functions of mutated p53 proteins in cellular reprogramming 
To study the effects of mutated TP53 in cellular reprogramming, we performed an 
overexpression experiment in human diploid fibroblasts. We found on counting the number of 
ES-like spheres that the reprogramming efficiency was high in the TP53 mutants R248W and 
R249S, but relatively low in the wild type TP53 and the TP53 mutants V143A and R175H.  
 
Comparison of the structures and functions of commonly studied TP53 mutants indicated that 
different mutants vary in their oncogenicity, and TP53 mutations in the core domain are classified 
into 2 types: class I and II mutations (12). Mutations such as those at the mutational hotspots 
R248 and R273 occur in the DNA contact areas on either the L3 loop or a nearby 
loop-sheet-helix motif of p53 (13) and are termed class I mutations. On the other hand, mutations, 
such as those at R175, occur in areas that are important for the conformational stability of p53 
protein, such as the L2 loop in the zinc region, and cause conformational changes; these 
mutations are termed as class II mutations. Such mutations expose the mutant-specific epitope 
of the antibody PAb240 but cause a loss of the wild-type-specific epitope that is detected by 
PAb1620 (13-15). The contact mutants may also evince other local conformational changes (16); 
in addition, they may vary in their degree of folding (12). In general, the conformational mutations 
are more oncogenic than the DNA-binding mutations in several systems (reviewed in (12)).  
 
Whether the TP53 mutants express normal p53 function with altered magnitudes, or whether 
they acquire novel functions remains debatable. Tumor-derived cell lines with the DNA contact 
R273H mutation exhibited wild-type p53 transcriptional activity, whereas cell lines with the R156P, 
R175H, R248W, R248Q, and R280K mutations did not (17), suggesting that the DNA contact 
TP53 mutant R273H, but not others, possessed wild-type p53 function. The DNA contact TP53 
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mutant R248, which in the present study showed high cellular reprogramming efficiency in the 
overexpression experiment, may express a novel function that is distinct from the wild-type p53 
transcriptional activity. Another conformational mutation, R249S, has been shown to cause only 
local structural changes and has a degree of folding similar to that of p53 proteins that were 
mutated at R248 (12) and exhibited high cellular reprogramming efficiency. The wild-type p53 
function in many DNA contact mutants, including R273H (18-20), R273C (20), R248Q (19, 20) as 
well as the closely related conformational mutant R249S (21), was successfully restored by 
using a synthetic peptide derived from the p53 C-terminal domain (19). The present study 
suggests that cellular reprogramming might be influenced by DNA-contact mutations, whereas 
the conformational mutations are more oncogenic than these DNA-binding mutations in several 
systems and likely to play critical roles in the development of human tumors. The above 
consideration may oversimplify the situation, because the present study used an overexpression 
strategy, and reprogramming efficiency was assessed by counting spheres formed at day 30. 
However, molecular manipulations of tumorigenicity and enhancement of the efficiency of 
cellular reprogramming by the p53 tumor suppressor pathway appear to be an attractive and 
useful concept for understanding normal and cancerous cells. 
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Figure Legends 
 
Fig. 1. Generation of induced pluripotent stem (iPS) cells. 
A, Schematic representation of iPS generation. Wild-type TP53 and the mutants of R175H or 
R248W were co-transfected with the 4 defined factors OCT4, SOX2, KLF4, and c-MYC into 
human diploid fibroblasts.  
B-D, Microscopic observation of iPS cells derived from human diploid fibroblasts co-transfected 
with the 4 defined factors and wild-type TP53 (B), mutant TP53 (R175H) (C), or mutant TP53 
(R248W) (D).  
 
Fig. 2. Immunostaining of iPS cells.  
The expression of Ssea-4 (B), Tra-1-60 (C), Tra-1-81 (E), and Tra-2-49 (F) proteins as examined 
by immunostaining with specific antibodies. A and B, controls.  
 
Fig. 3. Efficiency of iPS generation.  
Human diploid fibroblasts were co-transfected with the four defined iPS factors and wild-type 
TP53 gene or TP53 gene carrying mutations at positions 143, 175, 248, 249, or 273. 3F, 3 
defined factors Sox2, Oct3, and Klk4; 4F, 4 defined factors c-Myc and 3F; pMx, co-transfection 
with empty vector. At 30 days after transfection, colonies with iPS morphology were counted.  
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Fig. 1.  
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Fig. 2.  
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Fig. 3.  
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